Total Payments
$179,798
2024 Payments
$30,440
Companies
36
Transactions
351
Medicare Patients
1,891
Medicare Billing
$182,935
Payment Breakdown by Category
Research$173,849 (96.7%)
Food & Beverage$5,939 (3.3%)
Education$10.10 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $173,849 | 18 | 96.7% |
| Food and Beverage | $5,939 | 331 | 3.3% |
| Education | $10.10 | 2 | 0.0% |
Payments by Type
Research
$173,849
18 transactions
General
$5,949
333 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Janssen Research & Development, LLC | $122,619 | 11 | $0 (2024) |
| Eli Lilly and Company | $51,230 | 7 | $0 (2023) |
| AstraZeneca Pharmaceuticals LP | $954.09 | 49 | $0 (2024) |
| Novo Nordisk Inc | $831.04 | 46 | $0 (2024) |
| GlaxoSmithKline, LLC. | $766.66 | 43 | $0 (2024) |
| PFIZER INC. | $505.96 | 33 | $0 (2024) |
| Lilly USA, LLC | $360.29 | 22 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $269.55 | 16 | $0 (2024) |
| Merck Sharp & Dohme Corporation | $255.54 | 16 | $0 (2019) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $249.20 | 9 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $30,440 | 40 | Janssen Research & Development, LLC ($29,652) |
| 2023 | $81,354 | 44 | Janssen Research & Development, LLC ($78,968) |
| 2022 | $32,945 | 20 | Eli Lilly and Company ($18,658) |
| 2021 | $30,924 | 2 | Eli Lilly and Company ($30,924) |
| 2019 | $637.98 | 38 | AstraZeneca Pharmaceuticals LP ($139.68) |
| 2018 | $1,594 | 93 | AstraZeneca Pharmaceuticals LP ($257.93) |
| 2017 | $1,905 | 114 | GlaxoSmithKline, LLC. ($465.17) |
All Payment Transactions
351 individual payment records from CMS Open Payments — Page 1 of 15
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.62 | General |
| Category: Gastroenterology | ||||||
| 11/11/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $20.79 | General |
| Category: Biological | ||||||
| 10/31/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $13.97 | General |
| Category: Diabetes | ||||||
| 10/21/2024 | Novo Nordisk Inc | Ozempic (Drug), Rybelsus | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Diabetes | ||||||
| 10/17/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $14.49 | General |
| Category: Biological | ||||||
| 10/14/2024 | Astellas Pharma US Inc | Veozah (Drug) | Food and Beverage | In-kind items and services | $22.33 | General |
| Category: Biological | ||||||
| 10/10/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $24.67 | General |
| Category: Gastroenterology | ||||||
| 09/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $19.44 | General |
| Category: Gastroenterology | ||||||
| 09/19/2024 | Abbott Laboratories | FREESTYLE LIBRE 3 (Device) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Diabetes Care | ||||||
| 09/16/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $23.10 | General |
| Category: Endocrinology | ||||||
| 09/04/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $22.36 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 08/28/2024 | PFIZER INC. | OXBRYTA (Drug) | Food and Beverage | In-kind items and services | $21.82 | General |
| Category: HEMATOLOGY | ||||||
| 08/14/2024 | PFIZER INC. | PAXLOVID (Drug) | Food and Beverage | In-kind items and services | $20.97 | General |
| Category: INFECTIOUS DISEASES | ||||||
| 07/31/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $22.43 | General |
| Category: Diabetes | ||||||
| 06/19/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $18.08 | General |
| Category: Gastroenterology | ||||||
| 06/18/2024 | PFIZER INC. | VYNDAMAX (Drug) | Food and Beverage | In-kind items and services | $17.81 | General |
| Category: CARDIOVASCULAR | ||||||
| 06/12/2024 | GlaxoSmithKline, LLC. | SHINGRIX (Biological), AREXVY | Food and Beverage | In-kind items and services | $25.17 | General |
| Category: VACCINES | ||||||
| 06/06/2024 | Novo Nordisk Inc | — | Food and Beverage | In-kind items and services | $21.34 | General |
| 05/15/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $14.44 | General |
| Category: Diabetes | ||||||
| 05/08/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $19.02 | General |
| Category: Cardio-renal | ||||||
| 05/02/2024 | Dexcom, Inc. | Dexcom G6 Transmitter (Medical Supply) | Food and Beverage | In-kind items and services | $24.45 | General |
| Category: Endocrinology | ||||||
| 04/29/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $25.08 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/24/2024 | PFIZER INC. | ELIQUIS (Drug), PAXLOVID, NURTEC ODT | Food and Beverage | In-kind items and services | $25.04 | General |
| Category: CARDIOVASCULAR;METABOLIC DISEASE | ||||||
| 04/18/2024 | Lilly USA, LLC | JARDIANCE (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $21.46 | General |
| Category: Diabetes | ||||||
| 04/17/2024 | Lilly USA, LLC | MOUNJARO (Drug), ZEPBOUND | Food and Beverage | In-kind items and services | $15.25 | General |
| Category: Diabetes | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| 42847922ALZ2001 | Janssen Research & Development, LLC | $122,619 | 11 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF DONANEMAB IN EARLY SYMPTOMATIC ALZHEIMERS DISEASE | Eli Lilly and Company | $31,374 | 3 |
| ASSESSMENT OF SAFETY, TOLERABILITY, AND EFFICACY OF LY3372689 IN EARLY SYMPTOMATIC ALZHEIMER'S DISEASE | Eli Lilly and Company | $14,272 | 1 |
| A STUDY OF DONANEMAB VERSUS PLACEBO IN PARTICIPANTS AT RISK FOR COGNITIVE AND FUNCTIONAL DECLINE OF ALZHEIMER'S DISEASE | Eli Lilly and Company | $3,936 | 1 |
| A DONANEMAB (LY3002813) PREVENTION STUDY IN PARTICIPANTS WITH ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 3) | Eli Lilly and Company | $1,348 | 1 |
| A STUDY OF DONANEMAB (LY3002813) IN PARTICIPANTS WITH EARLY ALZHEIMER'S DISEASE (TRAILBLAZER-ALZ 2) | Eli Lilly and Company | $300.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 525 | 964 | $191,584 | $73,127 |
| 2022 | 7 | 349 | 566 | $128,714 | $47,264 |
| 2021 | 8 | 517 | 734 | $90,705 | $23,952 |
| 2020 | 8 | 500 | 904 | $92,914 | $38,592 |
Total Patients
1,891
Total Services
3,168
Medicare Billing
$182,935
Procedure Codes
30
All Medicare Procedures & Services
30 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 153 | 466 | $128,523 | $46,562 | 36.2% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2023 | 116 | 116 | $32,522 | $15,689 | 48.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 61 | 94 | $18,554 | $6,186 | 33.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 16 | 16 | $5,912 | $2,154 | 36.4% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 99 | 149 | $2,235 | $1,252 | 56.0% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2023 | 66 | 69 | $2,187 | $720.39 | 32.9% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 14 | 54 | $1,651 | $563.52 | 34.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 114 | 279 | $77,042 | $26,851 | 34.9% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2022 | 65 | 65 | $18,244 | $8,607 | 47.2% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 84 | 124 | $24,475 | $8,600 | 35.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 12 | 15 | $5,902 | $2,115 | 35.8% |
| 99212 | Established patient office or other outpatient visit, 10-19 minutes | Office | 2022 | 13 | 13 | $1,590 | $586.73 | 36.9% |
| 93000 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report | Office | 2022 | 32 | 34 | $1,078 | $398.61 | 37.0% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2022 | 29 | 36 | $384.00 | $106.53 | 27.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 119 | 206 | $43,370 | $11,733 | 27.1% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2021 | 90 | 90 | $28,481 | $5,512 | 19.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 44 | 56 | $8,479 | $2,863 | 33.8% |
| 99490 | Chronic care management services, first 20 minutes of clinical staff time per calendar month | Office | 2021 | 20 | 45 | $2,966 | $1,428 | 48.1% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2021 | 150 | 239 | $3,585 | $717.00 | 20.0% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 11 | 12 | $1,600 | $615.60 | 38.5% |
| G0444 | Annual depression screening, 15 minutes | Office | 2021 | 32 | 32 | $930.01 | $586.84 | 63.1% |
| 93000 | Routine ekg using at least 12 leads including interpretation and report | Office | 2021 | 51 | 54 | $1,294 | $497.37 | 38.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 105 | 154 | $29,240 | $12,266 | 41.9% |
| 99490 | Chronic care management services at least 20 minutes per calendar month | Office | 2020 | 77 | 353 | $24,004 | $11,205 | 46.7% |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 2020 | 71 | 71 | $22,367 | $8,462 | 37.8% |
About Dr. Ramon Leon, MD
Dr. Ramon Leon, MD is a Family Medicine healthcare provider based in Miami, Florida. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/17/2006. The National Provider Identifier (NPI) number assigned to this provider is 1073694337.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Ramon Leon, MD has received a total of $179,798 in payments from pharmaceutical and medical device companies, with $30,440 received in 2024. These payments were reported across 351 transactions from 36 companies. The most common payment nature is "" ($173,849).
As a Medicare-enrolled provider, Leon has provided services to 1,891 Medicare beneficiaries, totaling 3,168 services with total Medicare billing of $182,935. Data is available for 4 years (2020–2023), covering 30 distinct procedure/service records.
Ad
Practice Information
- Specialty Family Medicine
- Location Miami, FL
- Active Since 10/17/2006
- Last Updated 09/23/2021
- Taxonomy Code 207Q00000X
- Entity Type Individual
- NPI Number 1073694337
Products in Payments
- FARXIGA (Drug) $733.78
- XIFAXAN (Drug) $363.24
- Victoza (Drug) $320.95
- ANORO (Drug) $303.81
- ELIQUIS (Drug) $291.97
- BREO (Drug) $266.18
- JARDIANCE (Drug) $206.61
- CHANTIX (Drug) $198.93
- Tresiba (Drug) $183.18
- TOUJEO (Drug) $179.25
- TRULICITY (Drug) $172.01
- JANUVIA (Drug) $171.22
- BEVESPI AEROSPHERE (Drug) $153.91
- Ozempic (Drug) $151.03
- SHINGRIX (Biological) $141.26
- Androgel (Drug) $115.19
- OFEV (Drug) $108.80
- Rybelsus (Drug) $97.32
- Vascepa (Drug) $93.85
- Kerendia (Drug) $87.78
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Family Medicine Doctors in Miami
Keila Hoover, M.d, M.D
Family Medicine — Payments: $1.1M
Family Medicine $1.1M
Dr. Yamirka Duardo-Guerra, M.d, M.D
Family Medicine — Payments: $1.0M
Family Medicine $1.0M
Mirel Sanchez, M.d, M.D
Family Medicine — Payments: $165,828
Family Medicine $165,828
Gilberto Seco, Md, MD
Family Medicine — Payments: $127,612
Family Medicine $127,612
Dr. Clifford Kinder, Md, MD
Family Medicine — Payments: $121,261
Family Medicine $121,261
Ana Elosegui, M.d, M.D
Family Medicine — Payments: $51,214
Family Medicine $51,214